Anghel Sorina Andreea, Ioniță-Mîndrican Corina-Bianca, Luca Ioana, Pop Anca Lucia
Department of Clinical Laboratory, Food Safety, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia Street, 020945 Bucharest, Romania.
Department of Molecular Cell Biology, Institute of Biochemistry, Splaiul Independentei 296, 060031 Bucharest, Romania.
Cancers (Basel). 2021 Oct 2;13(19):4965. doi: 10.3390/cancers13194965.
In CRC, screening compliance is decreased due to the experienced discomfort associated with colonoscopy, although this method is the gold standard in terms of sensitivity and specificity. Promoter DNA methylation (hypomethylation or hypermethylation) has been linked to all CRC stages. Study objectives: to systematically review the current knowledge on approved biomarkers, reveal new potential ones, and inspect tactics that can improve performance. This research was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines; the risk of bias was evaluated using the revised Quality Assessment of Diagnostic Accuracy Studies criteria (QUADAS-2). The Web of Science Core Collection, MEDLINE and Scopus databases were searched for original articles published in peer-reviewed journals with the specific keywords "colorectal cancer", "early detection", "early-stage colorectal cancer", "epigenetics", "biomarkers", "DNA methylation biomarkers", "stool or blood or tissue or biopsy", "NDRG4", "BMP3", "SEPT9", and "SDC2". Based on eligibility criteria, 74 articles were accepted for analysis. mSDC2 and mSEPT9 were frequently assessed in studies, alone or together as part of the ColoDefense panel test-the latter with the greatest performance. mBMP3 may not be an appropriate marker for detecting CRC. A panel of five methylated binding sites of the CTCF gene holds the promise for early-stage specific detection of CRC. CRC screening compliance and accuracy can be enhanced by employing a stool mt-DNA methylation test.
在结直肠癌中，由于结肠镜检查会带来不适，导致筛查依从性降低，尽管就敏感性和特异性而言，这种方法是金标准。启动子DNA甲基化（低甲基化或高甲基化）与结直肠癌的各个阶段都有关联。研究目的：系统回顾关于已批准生物标志物的现有知识，揭示新的潜在生物标志物，并考察可提高性能的策略。本研究按照系统评价和Meta分析的首选报告项目（PRISMA）指南进行；使用修订后的诊断准确性研究质量评估标准（QUADAS-2）评估偏倚风险。在科学网核心合集、MEDLINE和Scopus数据库中检索发表在同行评审期刊上的原创文章，使用特定关键词“结直肠癌”“早期检测”“早期结直肠癌”“表观遗传学”“生物标志物”“DNA甲基化生物标志物”“粪便或血液或组织或活检”“NDRG4”“BMP3”“SEPT9”和“SDC2”。根据纳入标准，74篇文章被接受进行分析。在研究中，mSDC2和mSEPT9经常被单独或作为ColoDefense组合检测的一部分一起评估，后者性能最佳。mBMP3可能不是检测结直肠癌的合适标志物。CTCF基因的五个甲基化结合位点组成的组合有望用于结直肠癌的早期特异性检测。采用粪便线粒体DNA甲基化检测可提高结直肠癌筛查的依从性和准确性。
